[at noodls] – NEW YORK, April 10, 2013 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing of an underwritten public … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]
[at noodls] – NEW YORK, April 9, 2013 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it is offering to sell an aggregate … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to […]
[at noodls] – NEW YORK, March 18, 2013 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]
[at noodls] – NEW YORK, March 15, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that study results from the Phase IIb/III … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]
[at noodls] – NEW YORK, Feb. 22, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that President and CEO Gary S. Jacob, … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to […]
[at noodls] – NEW YORK, Feb. 11, 2013 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its common stock has been approved … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]
[at noodls] – SP-333 Advances to Multiple-Dosing Safety Study NEW YORK, Jan. 28, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders, announced today … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]
[at noodls] – NEW YORK, Jan. 15, 2013 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (Synergy) today announced that it convened its annual meeting of stockholders yesterday and it has received the necessary … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]
[at noodls] – NEW YORK, Jan. 3, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that it convened its annual meeting of stockholders on Thursday, January 3, 2013 and adjourned the meeting until Monday, … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to […]
[at noodls] – Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints NEW YORK, Jan. 2, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide, its investigational oral … moreView todays social media effects on SGYPView the latest stocks trending across Twitter. Click to view dashboardSee who Synergy is hiring next, click here to view […]
